Melita Sun Jung

Melita has led deals with a combined value over $5 billion, and upfront consideration exceeding $500 million. Recent partnerships include Sangamo’s Biogen CNS collaboration, Kite/Gilead gene editing oncology partnership, and Pfizer ALS collaboration; and the acquisition of TxCell, a leader in the emerging field of regulatory T cell therapies. Previously, Melita led business development and commercial teams at Adamas Pharmaceuticals, Ascendancy Healthcare, and Ipsen.

Melita started her career in venture capital and fund management, at Bay City Capital and Lombard Odier Darier Hentsch. She received her BA in Biology from the University of California at Berkeley.

‍